Breaking Finance News

Credit Suisse disclosed Zoetis Inc (NYSE:ZTS), hiking its price target to $67.00 earlier today

Reporting a potential upside of 0.07%, Credit Suisse upped the price target of Zoetis Inc (NYSE:ZTS) to $67.00

On Wednesday May 10, 2017, Jefferies & Co released a statement for Zoetis Inc (NYSE:ZTS) bumped up the target price from $65.00 to $70.00 that suggested an upside of 0.17%.

Boasting a price of $62.45, Zoetis Inc (NYSE:ZTS) traded -0.02% lower on the day. With the last stock price close up 5.71% from the two hundred day average, compared with the S&P 500 Index which has increased 0.02% over the date range. Zoetis Inc has recorded a 50-day average of $63.11 and a two hundred day average of $60.31. Volume of trade was down over the average, with 1,838,530 shares of ZTS changing hands under the typical 2,186,170

Performance Chart

Zoetis Inc (NYSE:ZTS)

With a total market value of $0, Zoetis Inc has price-earnings ratio of 36.04 with a one year low of $46.86 and a one year high of $65.83 .

A total of 10 equity analysts have released a ratings update on ZTS. zero equity analysts rating the company a strong buy, zero equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $52.70.

Brief Synopsis About Zoetis Inc (NYSE:ZTS)

Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Company's segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers. Its livestock products include Ceftiofur injectable line, Draxxin, Spectramast, Bovi-Shield line, Rispoval line, Suvaxyn/Fostera, Embrex devices and Lutalyse. Its companion animal products include Clavamox/Synulox, Convenia, ProHeart, Revolution/Stronghold, Apoquel, Cerenia and Rimadyl.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *